Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2017 10

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2017 10

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2017 12

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2017 13

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2017 14

2.4.1 Anthem Raises USD5.5 Billion in Private Placement of Notes 14

2.4.2 Celgene Prices USD3 Billion in Public Offering of Notes 14

2.4.3 Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 14

2.4.4 Nestle to Acquire Atrium Innovations for USD2.3 Billion 15

2.4.5 Eli Lilly and CureVac Enter into Partnership 15

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2017 17

3.1.1 Top M&A Deals in Q4 2017 18

3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2016 – Q4 2017 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2017 20

3.2.1 Top Initial Public Offerings in Q4 2017 21

3.2.2 Top Secondary Offerings in Q4 2017 21

3.2.3 Top PIPE Deals in Q4 2017 22

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2016 – Q4 2017 22

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2017 24

3.3.1 Top Venture Financing Deals in Q4 2017 25

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2017 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2017 26

3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2016 – Q4 2017 27

3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2016 – Q4 2017 28

3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2016 – Q4 2017 29

3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2017 30

3.5.1 Top Private Equity Deals in Q4 2017 31

3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2016 – Q4 2017 31

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2017 33

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2017 33

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2016 – Q4 2017 34

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2017 35

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2017 36

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2017 36

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2017 37

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 38

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2016 – Q4 2017 40

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2016 – Q4 2017 41

4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 42

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2017 44

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2017 44

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 45

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2017 46

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2017 46

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2017 47

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2016 – Q4 2017 48

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2016 – Q4 2017 49

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2016 – Q4 2017 51

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2016 – Q4 2017 52

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2016 – Q4 2017 54

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2017 56

6.1.1 Oncology – Deals of the Quarter 57

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2017 59

6.2.1 Central Nervous System – Deals of the Quarter 60

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2017 62

6.3.1 Infectious Disease – Deals of the Quarter 63

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2017 65

6.4.1 Immunology – Deals of the Quarter 66

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2017 68

6.5.1 Metabolic Disorders – Deals of the Quarter 69

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2017 72

6.6.1 Cardiovascular – Deals of the Quarter 73

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2017 75

6.7.1 Gastrointestinal – Deals of the Quarter 76

6.8 Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders Deals, Q4 2017 78

6.8.1 Musculoskeletal Disorders – Deals of the Quarter 79

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2017 81

6.9.1 Respiratory – Deals of the Quarter 82

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2017 84

6.10.1 Ophthalmology – Deals of the Quarter 85

7 Deal Summary by Geography 86

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2017 86

7.1.1 North America – Deals of the Quarter 87

7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2017 89

7.2.1 Europe – Deals of the Quarter 90

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2017 92

7.3.1 Asia-Pacific – Deals of the Quarter 93

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2017 95

7.4.1 Rest of the World – Deals of the Quarter 96

8 Pharmaceuticals & Healthcare, Global, Top Advisors 97

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2016 – Q4 2017 97

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2016 – Q4 2017 98

9 Further Information 99

9.1 Methodology 99

9.2 About GlobalData 100

9.3 Contact Us 100

9.4 Disclosure information 101

9.5 Disclaimer 101

Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 11

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2017 13

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2017 14

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2017 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2016 – Q4 2017 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2017 21

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2017 21

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2017 22

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 23

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 24

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2017 25

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2017 26

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 27

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 28

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2016 – Q4 2017 29

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 30

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2017 31

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 32

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 33

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 34

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 35

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2017 36

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2017 36

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2017 37

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 39

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2016 – Q4 2017 41

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 43

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 44

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 45

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2017 46

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2017 46

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2017 47

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 48

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2016 – Q4 2017 50

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2016 – Q4 2017 53

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 55

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 57

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 60

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 63

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 66

Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 69

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 73

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 76

Table 46: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 79

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 82

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 85

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 87

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 90

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 93

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 96

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 97

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 98

Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2017 12

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2017 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2016 – Q4 2017 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2016 – Q4 2017 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2016 – Q4 2017 22

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 24

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2017 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2017 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2016 – Q4 2017 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 28

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 30

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2016 – Q4 2017 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 33

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 38

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2016 – Q4 2017 40

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2016 – Q4 2017 41

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2016 – Q4 2017 42

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 44

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 45

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 48

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 49

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2016 – Q4 2017 51

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2016 – Q4 2017 52

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2016 – Q4 2017 54

Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 56

Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 59

Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 62

Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 65

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 68

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 72

Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 75

Figure 36: Pharmaceuticals & Healthcare, Global, Musculoskeletal Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 78

Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 81

Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 84

Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 86

Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 89

Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 92

Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 95

Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 97

Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2016 – Q4 2017 98

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017 thematic reports
Currency USD
$1,500

Can be used by individual purchaser only

$4,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017 in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2017 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.